Clinical trials: Advanced Adenomas
Colorectal Adenoma, Advanced Adenoma
Diagnostic Accuracy of M3 in Predicting Colorectal Advanced Adenoma Recurrence (M3-AA)
The investigators aim to evaluate the diagnostic accuracy of FIT and the novel panel of four bacterial gene markers collectively named as M3, to detect recurrent advanced adenomas in patients with history of colonic adenomas.
- Conditions
- Colorectal Adenoma, Advanced Adenoma, Colorectal Polyp
- Trial name
- M3-AA (NCT05144152)
- Testing
- M3, FIT
- Where
- Hong Kong
- Volunteers
- 600 people
- Sponsor
- Chinese University of Hong Kong
Neuroendocrine Tumor, Carcinoid Tumor
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00804336
- Testing
- SOM230, RAD001
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00416767
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Volunteers
- 20 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer, Colorectal Neoplasm
A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population
to determine screening value of stool-based SDC2 DNA methylation test for advanced colorectal neoplasia in the asymptomatic Chinese community population.
- Conditions
- Colorectal Cancer, Colorectal Neoplasm, Advanced Adenoma, Adenoma
- Trial name
- NCT04786704
- Testing
- Stool-based SDC2 DNA methylation test, quantitative Fecal immunochemical test
- Where
- China
- Volunteers
- 12,106 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Prostate Cancer, Adenocarcinoma of the Prostate
Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
Objective was to evaluate the efficacy and safety of the histrelin acetate subdermal implant (originally versus Lupron Depot-3 Month) in male patients with advanced prostate cancer during 52 weeks of treatment with the implant.
- Trial name
- NCT01697384
- Testing
- histrelin acetate
- Volunteers
- 138 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Advanced Solid Tumours, Cervical Cancer
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
This study is an open, multi-dose, dose escalation and cohort expansion, phase Ⅰ study to investigate the safety, tolerability, efficiency, pharmacokinetics, immunogenicity of SG001 in subjects with advanced tumours.
- Conditions
- Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma
- Trial name
- NCT03852823
- Testing
- SG001
- Where
- China
- Volunteers
- 192 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Colon Adenoma, Colon Polyp
St. Paul's Advanced Resection Center Cohort for Colorectal Neoplasia (SPARC-C)
The SPARC-C study is a prospective, multi-institutional observational study of patients referred for the management of large (≥ 20mm) non-pedunculated colorectal polyps (LNPCPs).
- Conditions
- Colon Adenoma, Colon Polyp, Colon Lesion
- Trial name
- SPARC-C (NCT05402696)
- Testing
- Endoscopic tissue resection
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 3,500 people
- Sponsor
- University of British Columbia
Mesothelioma, Malignant, Mesothelioma, Malignant Pleural
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma.
- Conditions
- Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
- Trial name
- NCT05188859
- Testing
- Sintilimab+Anlotinib+Pemetrexed+Cisplatin
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences